TAMs are an important source of pro-angiogenic factors in the TME; trabectedin significantly reduced the production of VEGF and angiopoietin-2 in macrophages and, accordingly, in tumor-bearing mice treated with the drug a clear decrease of the vessel network was observed (19, 20, 43). This evidence concerns the gene VEGFA and neoplasm.